PDF(Pubmed)
Abstract：
Pseudomonas aeruginosa (PA) is a prevalent opportunistic pathogen that has close associations with both acute and chronic infections. However, there exists an insufficiency of accurate and comprehensive data pertaining to the antimicrobial susceptibility patterns and clinical characteristics of both mucoid and non-mucoid strains of PA (mPA and non-mPA, respectively).
From January 1, 2021 to December 31, 2022, a thorough retrospective study was carried out to examine and compare the antibiotic susceptibility test outcomes and clinical characteristics of hospitalized patients with mPA and non-mPA infections.
This study investigated a cohort of 111 patients who were diagnosed with mPA infections, as well as 792 patients diagnosed with non-mPA infections. Significant demographic disparities, including gender (p < 0.001), age (p < 0.001), length of hospital stay (p < 0.001), diabetes (p = 0.043), and hypertension (p < 0.001), are evident between the mPA and non-mPA groups. The mPA group commonly necessitates hospitalization for respiratory system diseases, whereas the non-mPA group is associated with concomitant cardiovascular and cerebrovascular diseases. The mPA group demonstrates lower utilization rates of medical devices, such as Foley catheter (p < 0.001), nasogastric tube (p < 0.001), mechanical ventilation (p < 0.001), tracheostomy (p < 0.001), arterial and venous catheterization (p < 0.001), and exhibits superior organ function status, including lower incidences of hypoalbuminemia (p < 0.001), septic shock (p < 0.001), liver dysfunction (p < 0.001), renal failure (p < 0.001), and respiratory failure (p < 0.001). The non-mPA group is more vulnerable to infection with two or more bacterial pathogens compared to the mPA group, with the non-mPA group frequently resulting in Enterobacteriaceae infections and the mPA group being associated with fungal infections. Variations in antibiotic sensitivity are noted for Amikacin (p < 0.001), Ciprofloxacin (p < 0.001), Cefepime (p = 0.003), and Levofloxacin (p < 0.001) in antibiotic susceptibility testing, with resistance patterns closely tied to specific antibiotic usage.
There are significant demographic characteristics, clinical manifestations and antibiotic susceptibility between mPA and non-mPA infections. It is crucial to emphasize these characteristics due to their significant role in preventing and treating PA infections.
From January 1, 2021 to December 31, 2022, a thorough retrospective study was carried out to examine and compare the antibiotic susceptibility test outcomes and clinical characteristics of hospitalized patients with mPA and non-mPA infections.
This study investigated a cohort of 111 patients who were diagnosed with mPA infections, as well as 792 patients diagnosed with non-mPA infections. Significant demographic disparities, including gender (p < 0.001), age (p < 0.001), length of hospital stay (p < 0.001), diabetes (p = 0.043), and hypertension (p < 0.001), are evident between the mPA and non-mPA groups. The mPA group commonly necessitates hospitalization for respiratory system diseases, whereas the non-mPA group is associated with concomitant cardiovascular and cerebrovascular diseases. The mPA group demonstrates lower utilization rates of medical devices, such as Foley catheter (p < 0.001), nasogastric tube (p < 0.001), mechanical ventilation (p < 0.001), tracheostomy (p < 0.001), arterial and venous catheterization (p < 0.001), and exhibits superior organ function status, including lower incidences of hypoalbuminemia (p < 0.001), septic shock (p < 0.001), liver dysfunction (p < 0.001), renal failure (p < 0.001), and respiratory failure (p < 0.001). The non-mPA group is more vulnerable to infection with two or more bacterial pathogens compared to the mPA group, with the non-mPA group frequently resulting in Enterobacteriaceae infections and the mPA group being associated with fungal infections. Variations in antibiotic sensitivity are noted for Amikacin (p < 0.001), Ciprofloxacin (p < 0.001), Cefepime (p = 0.003), and Levofloxacin (p < 0.001) in antibiotic susceptibility testing, with resistance patterns closely tied to specific antibiotic usage.
There are significant demographic characteristics, clinical manifestations and antibiotic susceptibility between mPA and non-mPA infections. It is crucial to emphasize these characteristics due to their significant role in preventing and treating PA infections.
摘要：
■铜绿假单胞菌（PA）是一种流行的机会性病原体，与急性和慢性感染密切相关。然而,关于PA的粘液性和非粘液性菌株（mPA和非mPA，分别)。
■从2021年1月1日至2022年12月31日，进行了一项全面的回顾性研究，以检查和比较mPA和非mPA感染的住院患者的抗生素敏感性试验结果和临床特征。
■这项研究调查了111名被诊断为mPA感染的患者，以及792例诊断为非mPA感染的患者。巨大的人口差异，包括性别（p<0.001），年龄（p<0.001），住院时间（p<0.001），糖尿病（p=0.043），和高血压（p<0.001），在mPA和非mPA基团之间是明显的。mPA组通常需要住院治疗呼吸系统疾病，而非mPA组与伴随的心脑血管疾病有关。mPA小组显示医疗设备的利用率较低，如Foley导管（p<0.001），鼻胃管（p<0.001），机械通气（p<0.001），气管造口术（p<0.001），动脉和静脉导管插入术（p<0.001），并表现出优越的器官功能状态，包括低白蛋白血症发生率较低（p<0.001），感染性休克（p<0.001），肝功能障碍（p<0.001），肾功能衰竭（p<0.001），和呼吸衰竭（p<0.001）。与mPA组相比，非mPA组更容易感染两种或两种以上的细菌病原体，非mPA组经常导致肠杆菌感染，而mPA组与真菌感染有关。阿米卡星的抗生素敏感性变化（p<0.001），环丙沙星（p<0.001），头孢吡肟（p=0.003），和左氧氟沙星（p<0.001）在抗生素药敏试验中，耐药模式与特定的抗生素使用密切相关。
■有显著的人口统计学特征，mPA和非mPA感染的临床表现和抗生素敏感性。由于它们在预防和治疗PA感染中的重要作用,强调这些特征是至关重要的。
■从2021年1月1日至2022年12月31日，进行了一项全面的回顾性研究，以检查和比较mPA和非mPA感染的住院患者的抗生素敏感性试验结果和临床特征。
■这项研究调查了111名被诊断为mPA感染的患者，以及792例诊断为非mPA感染的患者。巨大的人口差异，包括性别（p<0.001），年龄（p<0.001），住院时间（p<0.001），糖尿病（p=0.043），和高血压（p<0.001），在mPA和非mPA基团之间是明显的。mPA组通常需要住院治疗呼吸系统疾病，而非mPA组与伴随的心脑血管疾病有关。mPA小组显示医疗设备的利用率较低，如Foley导管（p<0.001），鼻胃管（p<0.001），机械通气（p<0.001），气管造口术（p<0.001），动脉和静脉导管插入术（p<0.001），并表现出优越的器官功能状态，包括低白蛋白血症发生率较低（p<0.001），感染性休克（p<0.001），肝功能障碍（p<0.001），肾功能衰竭（p<0.001），和呼吸衰竭（p<0.001）。与mPA组相比，非mPA组更容易感染两种或两种以上的细菌病原体，非mPA组经常导致肠杆菌感染，而mPA组与真菌感染有关。阿米卡星的抗生素敏感性变化（p<0.001），环丙沙星（p<0.001），头孢吡肟（p=0.003），和左氧氟沙星（p<0.001）在抗生素药敏试验中，耐药模式与特定的抗生素使用密切相关。
■有显著的人口统计学特征，mPA和非mPA感染的临床表现和抗生素敏感性。由于它们在预防和治疗PA感染中的重要作用,强调这些特征是至关重要的。
